| Literature DB >> 35431909 |
Wyllians Vendramini Borelli1,2, Priscylla Nunes de Senna1, Wagner Scheeren Brum3, Artur Francisco Schumacher-Schuh1,4, Eduardo R Zimmer2,3,4, Márcia Lorena Fagundes Chaves1, Raphael Machado Castilhos1.
Abstract
Introduction: Functional Cognitive Disorder (FCD) is a non-degenerative, common cause of memory complaint in patients with high educational levels. FCD has been insufficiently described in individuals with low education. Here, we investigated the frequency of FCD among individuals with low education.Entities:
Keywords: Alzheimer’s disease; cognitive complaint; dementia; major depression; public health; subjective cognitive decline; subjective memory impairment
Year: 2022 PMID: 35431909 PMCID: PMC9011344 DOI: 10.3389/fnagi.2022.789190
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.702
Demographic and clinical characteristics of patients that attended the memory clinic within the period of 2014–2021.
| Functional cognitive disorder ( | Mild cognitive impairment ( | Neurodegenerative disorders ( | Corrected | |
| Age, mean (SD) | 66.2 (± 9.4) | 73.7 (± 8.4) | 72.4 (± 10.4) |
|
| Sex (F) | 100 (68.5%) | 29 (56.9%) | 174 (58.2%) | 0.87 |
| Education, mean (SD) | 5.6 (± 3.9) | 5.3 (± 3.9) | 4.9 (± 4.0) | 0.17 |
| Mini-mental state examination, mean (SD) | 22.4 (± 6.2) | 21.4 (± 4.4) | 13.6 (± 7.6) |
|
| Geriatric depression scale–15 item, mean (SD) | 7.4 (± 4.5) | 3.5 (± 3.0) | 5.7 (± 3.7) |
|
| Functional assessment questionnaire, mean (SD) | 6.9 (± 7.6) | 6.2 (± 5.7) | 20.2 (± 8.4) |
|
|
| ||||
| Active smoking | 13 (8.9%) | 6 (11.8%) | 22 (7.4%) | 0.82 |
| Active alcohol drinking | 5 (3.4%) | 3 (5.9%) | 12 (4.0%) | 0.55 |
|
| ||||
| Hypertension | 83 (56.8%) | 34 (66.7%) | 187 (62.5%) | 0.37 |
| Diabetes | 33 (22.6%) | 17 (33.3%) | 83 (27.8%) | 0.26 |
| Dyslipidemia | 31 (21.2%) | 20 (39.2%) | 75 (25.1%) | 0.04 |
| Malignancy | 7 (4.8%) | 3 (5.9%) | 22 (7.4%) | 0.65 |
| Heart failure | 5 (3.4%) | 0 | 10 (2.9%) | 0.57 |
| Hypothyroidism | 14 (9.6%) | 5 (9.8%) | 23 (7.7%) | 0.69 |
| Major depression | 25 (17.1%) | 3 (5.9%) | 16 (5.4%) |
|
|
| ||||
| Anti-hypertensive drug | 79 (54.5%) | 32 (62.7%) | 170 (57.0%) | 0.6 |
| Antidepressant drug | 69 (47.6%) | 14 (27.5%) | 106 (35.6%) | 0.01 |
| Antipsychotic drug | 33 (22.8%) | 3 (5.9%) | 85 (28.5%) | 0.0007 |
| Acetylcholinesterase inhibitor | 5 (3.4%) | 4 (7.8%) | 58 (39.7%) |
|
| Benzodiazepines | 20 (13.8%) | 5 (9.8%) | 34 (11.4%) | 0.8 |
FCD, functional cognitive disorder; MCI, mild cognitive impairment; NDD, neurodegenerative disorders. Bold represents statistically significant p-values.
FIGURE 1Frequency of diagnosis. The circle represents the frequency of diagnosis in our sample (n = 516), from 2014 to 2020. FCD, functional cognitive disorder; AD, Alzheimer’s disease; MCI, mild cognitive impairment; VD, vascular dementia; bvFTD, behavioral variant frontotemporal dementia; LBD, lewy bodies dementia.
FIGURE 2Number of new appointments in the memory clinic studied. Relative percentages represent the number of diagnoses of FCD divided by total new appointments of the corresponding year. FCD, functional cognitive disorder; MCI, mild cognitive impairment; NDD, neurodegenerative disorders. *Decrease in total number of appointments related to Coronavirus disease pandemic.
Logistic regression model using diagnosis of neurodegenerative disorder as outcome.
| Variable | Estimate | OR (95% CI) | ||
| Age | 0.05 | 0.01 | 0.006 | 1.06 (1.03–1.08) |
| Education | 0.09 | 0.03 | <0.001 | 1.09 (1.02–1.17) |
| MMSE scores | −0.16 | 0.02 | <0.001 | 0.84 (0.8–0.88) |